Last update 01 Nov 2024
D1 receptor x VDCCs x CAs x SCNA x D2 receptor x 5-HT2 receptor
Last update 01 Nov 2024
Basic Info
Related Targets |
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis
100 Clinical Results associated with D1 receptor x VDCCs x CAs x SCNA x D2 receptor x 5-HT2 receptor
Login to view more data
100 Translational Medicine associated with D1 receptor x VDCCs x CAs x SCNA x D2 receptor x 5-HT2 receptor
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free